Campbell Soup has sold its Habit personalised nutrition business to healthcare company Viome.
Habit was founded in 2015 with a mission to transform human health through its proprietary testing methodologies and personal nutrition guidance. Campbell Soup has been the business’s sole strategic investor and majority shareholder since its inception.
Viome said the acquisition will allow it to expand its core offering by tapping into Habit’s “robust insights for consumer behaviour modification”. With this, both companies aim to provide a richer consumer experience and deepen personalised recommendations with nutrition plans and engagement tools.
US-based Viome uses artificial intelligence to understand what is going on inside the body at a molecular level. It targets the bacteria, viruses, yeast, fungus and mould in the system that work symbiotically with the body to provide the nutrition needed to feel energetic and stay healthy.
“With Habit now part of Viome, we have the perfect articulation of personalised health,” said Viome founder and CEO Naveen Jain.
“I have always admired Habit’s ability to engage and motivate the consumer. Combined with Viome’s deep insights from the microbiome, we are able to see the complete story our body is telling us about our overall health.”
Habit founder and CEO Neil Grimmer added: “With the advent of big data and computational biology, I believe it’s possible to provide everyone in this country and around the world a personalised blueprint to achieve their health and wellness goals.
“Viome analyses the gut microbiome at a molecular level with advanced technology from the Los Alamos National Lab, which is a great competitive advantage and great foundation for creating the ultimate whole-body nutrition solution.”
The new center of expertise illustrates Roquette’s strategy of making its Vic-sur-Aisne site a dedicated place for plant protein development. This center will be a major asset to design the future technological processes that will bring new plant protein properties.
The new state-of-the-art facility will prioritise “sustainable production with advanced CO2 emission reductions and biomass reuse,” a company statement said. It will also enable Cargill to meet increasing demand for clean label texturising ingredients.
The move will assist in repaying outstanding debt (circa €1.6 billion or US$1.9 billion), while providing the company with increased financial flexibility. The IPO is also expected to support Azelis’ growth strategy and future acquisitions by providing funding and giving it access to capital markets.